Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

Insulin resistance is documented in clamp studies in 75% of women with polycystic ovary
syndrome (PCOS). Although it is not included in the diagnostic criteria of PCOS, there is a …

Abstract Purpose of Review To discuss evidence supporting the use of glucagon-like
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …

Abstract Purpose Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have
become increasingly popular as both diabetic and weight loss therapies. One effect of this …

Obesity remains a major public health problem, affecting almost half of adults in the United
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …

Obesity is a complex metabolic condition that can have a negative impact on one's health
and even result in mortality. The management of obesity has been addressed in a number of …

Abstract Context Prader–Willi syndrome (PWS) is characterized by lack of appetite control
and hyperphagia, leading to obesity. Pharmacological options for weight management are …

It is known that nitric oxide (NO) plays a key physiological role in the control of
gastrointestinal (GI) motor phenomena. In this respect, NO is considered as the main non …

This review investigates the various pharmacologic treatments for overweight and obesity in
adults, especially glucagon-like peptide 1 (GLP-1) agonists. In light of the globally …